Company: FVN
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001829126-25-005949
Chunk: 94

Company: Future Vision II Acquisition Corp.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 2
Chunk 94
---
, and there can
be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over
financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal
quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

26

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors.

Factors that could cause our actual results to differ
materially from those in this Quarterly Report include the risk factors described in the registration statements on Form S-1 and the annual
report on Form 10-K for our IPO filed with the SEC. As of the date of this Quarterly Report, there have been no material changes to the
previously disclosed risk factors.

Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds.

On February 27, 2024, our Sponsor paid an aggregate
of $25,000, or approximately $0.017 per share, for the purchase of 1,437,500 founder shares, par value $0.0001. Our Sponsor is an accredited
investor for purposes of Rule 501(a) of Regulation D of the Securities Act of 1933, as amended. Each of the equity holders in our
Sponsor are accredited investors under Rule 501(a) of Regulation D. The sole business of our Sponsor is to act as the Company’s
sponsor in connection with this offering.

On September 13, 2024, we consummated our IPO
of 5,000,000 Units, at $10.00 per Unit, generating gross proceeds of $50,000,000. We granted the underwriter a 45-day option to purchase
up to an additional 750,000 Units at the IPO price to cover over-allotments. As of September 13, 2024, the over-allotment option
was exercised, generating gross proceeds of $7,500,000 and deposited into the Trust Account. Meanwhile, 57,500 ordinary shares were issued
to the underwriter at the closing of the IPO as representative shares, and 28,750 representative shares will be issued as the deferred
underwriting commission at the consummation of a Business Combination. The securities sold in the